Composite hydrogels for bone regeneration by Tozzi, Gianluca et al.
materials
Review
Composite Hydrogels for Bone Regeneration
Gianluca Tozzi 1, Arianna De Mori 2, Antero Oliveira 2 and Marta Roldo 2,*
1 School of Engineering, University of Portsmouth, Anglesea Building, Anglesea Road,
Portsmouth PO1 3DJ, UK; gianluca.tozzi@port.ac.uk
2 School of Pharmacy and Biomedical Science, University of Portsmouth, St Michael’s Building,
White Swan Road, Portsmouth PO1 2DT, UK; arianna.demori@port.ac.uk (A.D.M.);
antero.oliveira@port.ac.uk (A.O.)
* Correspondence: marta.roldo@port.ac.uk; Tel.: +44-239-284-3586
Academic Editor: Michael Nerlich
Received: 2 February 2016; Accepted: 29 March 2016; Published: 2 April 2016
Abstract: Over the past few decades, bone related disorders have constantly increased. Among
all pathological conditions, osteoporosis is one of the most common and often leads to bone
fractures. This is a massive burden and it affects an estimated 3 million people only in the UK.
Furthermore, as the population ages, numbers are due to increase. In this context, novel biomaterials
for bone fracture regeneration are constantly under development. Typically, these materials aim at
favoring optimal bone integration in the scaffold, up to complete bone regeneration; this approach
to regenerative medicine is also known as tissue engineering (TE). Hydrogels are among the most
promising biomaterials in TE applications: they are very flexible materials that allow a number
of different properties to be targeted for different applications, through appropriate chemical
modifications. The present review will focus on the strategies that have been developed for
formulating hydrogels with ideal properties for bone regeneration applications. In particular, aspects
related to the improvement of hydrogels’ mechanical competence, controlled delivery of drugs
and growth factors are treated in detail. It is hoped that this review can provide an exhaustive
compendium of the main aspects in hydrogel related research and, therefore, stimulate future
biomaterial development and applications.
Keywords: biomaterials; regenerative medicine; hydrogels; bone regeneration; tissue engineering;
mechanical properties; growth factors; statins; bisphosphonates; hydroxyapatite
1. The Bone
The bone is a solid composite living material that represents the main constituent of the vertebral
skeleton [1]. This dynamic tissue plays many important roles in the human body: first of all, by a joint
action with the digestive and renal systems, it contributes to the regulation of the concentration of
electrolytes, such as Ca and P [2,3]. Secondly, its hard and moderately elastic nature allows it to provide
a framework for the support and attachment of softer tissues such as muscles, and for the protection of
vital organs and the bone marrow. Finally, it provides all the necessary body support for locomotion
and muscular contraction [4].
1.1. Bone Anatomy
The bone is typically composed of an outer layer of compact bone (also called cortical bone)
embedding an inner spongy bone structure (also called trabecular or cancellous bone). Trabecular
bone is formed by various trabeculae arranged in a honeycomb structure. The relative proportion
between the cortical and trabecular bone varies with the skeletal segments and their function. The
major difference between compact and trabecular bone lies in their porosity that ranges from 5% to
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30% in the compact bone and from 30% to 90% in the trabecular bone. Long bones (i.e., humerus and
femur) are constituted by three regions: diaphysis, the central shaft; epiphysis, the bulbous extremities;
and metaphysis, located between the two. In the middle of the shaft, a medullary (or marrow cavity)
is present; this contains red bone marrow for hematopoiesis during infancy and additionally yellow
marrow for energy storage during adulthood. Short bones include the tarsal and carpal bones; flat
bones include the frontal and parietal bones of the cranium, ribs, scapula and pelvis; finally, irregular
bones include the bones of the spine (vertebrae, sacrum and coccyx) and some bones of the skull such
as sphenoid and ethmoid [5,6]. Bone shape is genetically determined in order to satisfy particular
requirements according to the anatomic position and function. Furthermore, during life, bone shape
is altered by the process known as remodelling, based on a combination of periosteal and endosteal
apposition and resorption [7–9].
1.2. Chemical Composition
At a microscopic level, bone can be divided into three main components: matrix, cells and
bioactive factors. The calcified bone matrix is formed by an organic protein-rich matrix (20% of dry
weight), a mineral substance (65%) and water (~10%). The organic phase has a role in determining
the form of the bone and affords resistance to tension. The major component of the organic matrix is
collagen type I (90%); the remaining 10% is constituted of non-collagenous proteins, proteoglycans
and phospholipids. Moreover, the matrix contains growth factors and enzymes such as phosphatase
and metalloproteinase. Collagen fibrils are formed by three filamentous polypeptide chains in a
helical configuration, which are stabilised through intra- and intermolecular cross-links that enhance
the tensile strength of the fibrils. The non-collagenous proteins have different functions in the bone
structure; phospholipids and proteoglycans have a regulatory effect in the calcification process [4].
The inorganic phase serves as an ion reservoir (predominately Ca, Mg, Na and P) and increases the
strength of the bone due to the presence of apatite, carbonate, acid phosphate and brushite. The main
inorganic component of the bone is hydroxyapatite [Ca10(PO4)6(OH)2] [10,11].
1.3. Histology of the Bone
The bone consists of cells from two cell lineages: mesenchymal stem cells (MSC) and hematopoietic
stem cells (HSC).
1. MSCs are multipotent stromal cells that can differentiate into diverse cell types such as myocytes
and adipocytes but also osteoblast progenitors, osteoblasts, bone-lining cells, chondrocytes and
osteocytes. Osteoblasts are the most prevalent cell type in the bone and their function is to secrete
matrix components, such as collagen I, in response to mechanical stimuli, and to promote the
mineralisation of the bone matrix. Osteocytes, derived from osteoblasts, have mechanosensor and
modulator (promotion of nerve growth) activities. Bone-lining cells are instead able to release
enzymes to remove the layer of osteoids that covers mineralised matrix, allowing osteoclasts to
attach and begin resorption.
2. HSCs are stem cells that give rise to blood cells such as monocyte, macrophages or platelets,
but also preosteoclasts and osteoclasts. Osteoclasts are responsible for bone resorption; by the
secretion of protons, they can lower the pH and so solubilize the mineral phase. These cells are
responsible for an intricate balance between formation, maintenance and destruction of bone
tissue. This equilibrium is maintained by mechanical factors and the action of cytokines and
hormones, such as calcitonin and parathyroid hormone (PTH), which can control the levels of
calcium and phosphate in the blood. Calcitonin is a thyroid hormone that reduces blood calcium
levels by inhibiting osteoclasts and decreasing Ca resorption in the kidneys. Conversely, PTH is a
hormone that increases blood calcium levels, acting upon the PTH1 receptor in bone and kidney,
and the PTH2 receptor in the central nervous system, pancreas, testis, and placenta [6].
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It is evident from the above brief description that the bone is an extremely complex tissue and
that many factors can play a role in its physiology and function.
1.4. Bone Healing
The bone tissue possesses an intrinsic capacity of healing itself; the bone repairing process is an
interplay of biomechanical, cellular and molecular factors [12]. If successful, bone regenerates itself
with newly formed bone in children and in a mechanically stable lamellar structure in adults. These
are formed after remodelling of newly formed woven bone [13]. The full understanding of this process
may help researchers to develop new strategies to treat slowly healing or non-healing fractures [14].
First of all, when a fracture occurs, the following local tissue damage is observed: interruption of
skeletal integrity, disruption of vascular structures and of nutrient flow at the fracture site, leading to a
reduced oxygen tension and disruption of marrow architecture [15]. These are the prelude to the real
bone regeneration process [16]. The bone healing process is divided into three phases: inflammation
phase, reparative phase and remodelling phase (Figure 1) [13]. During the inflammation phase, blood
vessel disruption causes the formation of a blood clot, called haematoma. Later, the immigrating
platelets, neutrophils and macrophages release signalling molecules, such as fibroblast growth factors
(FGF), tumour necrosis factor-↵ (TNF-↵), platelet-derived growth factors (PDGF), vascular endothelial
growth factor (VEGF), basic fibroblast growth factor (BFGF), transforming growth factor (TGF- ) and
cytokines, such as IL-1 and IL-6 [15]. Then, IL-1 and IL-6 chemotactically attract mesenchymal cells
precursors [16]. Finally, mesenchymal precursors proliferate and differentiate into the chondrogenic
and osteogenic lineages [15]. During the second phase, or reparative phase, chondroblasts form hyaline
cartilage while osteoblasts formwoven bone that bridges and stabilises the bone wound. The so formed
woven and hyaline cartilage is then substituted by lamellar tissue following a tissue-mineralisation
process. The calcified tissue is then penetrated by blood vessels and the cartilaginous septum removed.
The last phase is the remodelling phase during which the fracture callus is converted into new bone.
In this phase, osteoclasts are responsible for resorption of trabecular bone, creating a shallow resorption
pit, called Howship’s lacunae. Then, an enzymatic destruction of the bone matrix, promoted by the
locally present cells, leads to the release of growth factors and cytokines. The latter induces the
conversion of osteoprogenitor cells to osteoblasts that fill the resorption pits created by osteoclasts to
create new bone matrix. Finally, the cells entrapped within the bone matrix generate osteocytes [15].
 
Figure 1. Bone healing process. BMP-2: bone morphogenetic protein-2.
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2. Bone Tissue Engineering
2.1. The Need for Effective Bone Repair Strategies: Economic, Social and Clinical Aspects
Over the past few decades, the prevalence of bone related disorders has steadily been on the
rise [17]. The most notable cause for this is our increasingly aging population, however, other factors
such as disease (i.e., Paget’s disease or osteoporosis) and recurrent sports injuries are also relevant [18].
While these issues may have taken a back seat in comparison to the attention that heart disease
and cancer have attracted, bone diseases are common and significant healthcare issues, and this has
prompted a steady stream of research in the field of bone regenerative medicine [17].
Osteoporosis is one of the most common diseases leading to bone fractures; it affects an estimated
3 million people in the UK, and, as the population ages, numbers are due to increase [19]. The National
Institute for Health and Care Excellence has published a guidance indicating that the direct cost from
fragility related fractures in the year 2000 was estimated to be £1.8 billion, with the potential to increase
to £2.2 billion by 2025 and to reach £6 billion by 2036, in the UK only [20].
Bone fractures also have a great impact on patients’ quality of life; for example, they can infringe
on the ability of a person to live independently, when the fracture occurs along a load bearing bone,
or they can affect self-esteem and social interaction when the spine and the posture of the patient
are affected. They can also lead to high mortality in the elderly [19,20]. Moreover, co-morbidities
can reduce the bone regeneration capacity with recurrence of delayed- or non-union fractures; these
significantly prolong the recovery period and constitute a considerable societal burden [21].
2.2. Limitations of the Current Treatments
Current treatment protocols for complex bone fractures involve the use of auto-/allo-grafts or
inert metallic/ceramic implants. Autograft implantation represents the golden standard for treatment
of small bone defects [22]. This technique transplants the donor’s bone from a non-load-bearing
site of the patient (i.e., iliac crest) into the defect site in the same patient [23]. Bone autografting
presents all the essential elements to heal a bone fracture, since the transplanted bone tissue has
osteoconductive, osteoinductive and osteogenic properties. However, autografting shows some
disadvantages such as high costs and limited available tissue from donor sites. Allograft is the second
most common bone-grafting technique. This method involves the transplantation of bone from a
different donor (i.e., cadavers) and the main shortcomings are related to infections and demand of
donor bone tissue [24]. When both auto- and allografts are not successful or adequate, different
biomaterials are considered. Metallic devices such as plates/screws, rods and fixators are widely
used, but despite their excellent mechanical properties, they are not bioactive or bioresorbable, thus
limiting their performance and requiring additional surgical procedures in case of revision [25].
Moreover, due to stress shielding effects, they can cause bone resorption and consequent implant
loosening [25]. Ceramics represent a valuable alternative due to their availability and adaptation
to various applications. Calcium phosphate (CaP) cements, for instance, well resemble bone tissue
chemical/functional properties, being both biocompatible and bioactive. However, low tensile strength
and high brittleness are among the main drawbacks of such materials [26,27]. CaP showed ability in
promoting bone repair, although they typically provide poor revascularisation/mineralisation, limited
life-time, and inability to adapt to skeletal changes [28]. Furthermore, a single-phased material cannot
efficiently guarantee bone growth, and tissue engineering approaches are needed [29].
2.3. Requirements for Successful Development of Bone Tissue Engineering Scaffolds
As reported by the pioneers Langer and Vacanti, the term tissue engineering (TE) defines
“an interdisciplinary field that applies the principles of engineering and life sciences toward the
development of biological substitutes that restore, maintain, or improve tissue or organ function” [30].
In general, TE aims at developing temporary 3D multicomponent scaffolds, also called composites,
to induce the physiological regeneration of functional tissues (i.e., bone), overcoming the downfalls
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of currently available biomaterials systems [25,31,32]. Scaffolds are firstly intended to work as
fillers, occupying the available space in the damaged organ/tissue and slowly their programmed
bioerosion/resorption activity allows them to provide a framework for growth of new tissue that finally
(partially or completely) replaces the scaffold. Polymers’ bioerosion kinetics can be controlled, in order
to be adjusted to in vivo bone formation rate, by modifying molecular weight, degree of modification,
degree of crosslinking and by blending with different polymers. Saravanan et al. reviewed some
conditions that can, for example, affect the rate of degradation of chitosan-based scaffolds [33].
An ideal scaffold for bone tissue engineering (BTE) must present the following three main
properties [34]:
1. Osteoconduction refers to the growth of new tissue on the external and internal (pores) surfaces
of the implant. This is greatly dependent on the physical form and chemical composition of
the material. Factors such as hydrophilicity, porosity, biocompatibility and biodegradability
of the material will affect its osteoconductive properties. For example, porosity (optimal pore
size 200–350 µm) is crucial for allowing neovascularisation and diffusion of nutrients and gases
required for the formation of the new bone [35]. Mechanical competence of the material is also
important to provide an osteoconductive scaffold. This review will look at different approaches
that have been studied in an attempt to improve the mechanical performance of hydrogel scaffolds.
2. Osteogenicity is the property of those scaffolds that contain osteoprogenitor cells and favour their
adhesion and proliferation [36]. This review will look at the different types of stem cells that can
be used in bone regeneration and strategies for their inclusion in hydrogel scaffolds.
3. Osteoinduction is the capacity of attracting immature cells to a healing site and stimulating these
cells to develop into bone-forming cells. Materials that are osteoinductive are able to induce bone
formation in ectopic sites [34]. This review will consider the complexity of controlled delivery of
drugs and growth factors from bone regeneration scaffolds.
Osteointegration, defined at a histological level as the direct contact between the implant and the
new bone without the formation of fibrous tissue and the ability to maintain a strong biomaterial/bone
interaction over time, should be the overall outcome of the application of a scaffold that presents all the
properties described above. Importantly, osteointegrated implants should re-establish the mechanical
function of the repaired bone.
3. Hydrogels as Scaffolds and Delivery Platforms
In their letter to Nature in 1960, Wichterle and Lim investigated for the first time the role of
hydrogels for biological use [37]; the following decades have seen a wealth of research aimed at
exploiting the particular properties of hydrogels that allow their use for many purposes such as:
matrices for tissue engineering and regenerative medicine, diagnostics, cellular immobilisation,
separation of biomolecules or cells and barrier materials to regulate biological adhesion [10,38].
Hydrogels are three dimensional, hydrophilic, cross-linked polymeric networks [38,39]. They are
able to swell without disintegrating and can absorb up to several times their dry weight in water [40].
Their high content in water makes them resemble the living tissue; therefore, they are ideal for a wide
range of biomedical and pharmaceutical applications [41]. Hydrogels can be produced by different
techniques: one-step methods like polymerisation and parallel cross-linking of multifunctional
monomers, or multiple-step methods by the synthesis of polymer molecules characterised by the
presence of reactive groups that originate cross-links in presence of low molecular weight crosslinking
agents [42]. The crosslinking points are essential to avoid the dissolution of the polymer chains and
the type and degree of crosslinking determine many of the properties of the hydrogel [41]; for example,
crosslinking establishes the mesh size of the polymeric network and the water content that the gel
can reach [42]. While the hydrophilic groups of the network chains attract and hold the fluid, the
cross-links inside the structure impart an elastic force responsible for the solidity and stress-resistance
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of the hydrogel [41,42]. Hydrogel preparation techniques and considerations needed in their design
have recently been reviewed by Sivashanmugam et al. [43].
Hydrogels are very flexible materials, amenable to different chemical modifications that can tune
the desired properties according to the intended application. The present review will focus on the
strategies that have been developed in the formulation of hydrogels with ideal properties for bone
regeneration applications: osteoconduction, osteoinduction and osteogenicity.
3.1. Osteoconductive Composite Hydrogels: Strategies to Improve Hydrogels Mechanical Competence
It is widely accepted that scaffolds used for bone tissue engineering should be able to provide
temporary mechanical integrity at the defect site immediately upon implantation. The mechanical
properties of scaffolds should be tailored to match the demands of the implant site to decrease or avoid
complications such as stress shielding, implant-related osteopenia, and subsequent re-fracture [44,45].
Consequently, the design of the scaffold will vary with the site of implantation and with the type of
bone. However, specific mechanical requirements for scaffolds are still to be defined by the research
community and clinicians.
The soft nature of hydrogels makes them unsuitable for applications where a certain mechanical
competence is required and, although the mechanical properties of hydrogels can be increased by
manipulating a number of parameters such as type and density of crosslinking [46], polymeric
molecular weight, chemistry/concentration of the hydrogel precursors, it is not always possible to
achieve the desired properties [47]. It must be also considered that some changes to the hydrogel
formulation such as the use of high crosslinking density may lead to toxicity as well as a limit in the
diffusion of loaded drugs, or the migration of cells and the exchange of gasses and nutrients that are
essential for the healing of the fractured bone [48]. Therefore, designing hydrogel composites that are
capable of synergising the biocompatibility and flexibility of the polymeric network and the structural
support provided by the filler materials, can enhance the mechanical performance of hydrogels without
affecting their beneficial properties. This results in a biomimetic approach where the physicochemical
properties of nanostructured hybrid materials can stimulate cell growth and guide bone healing [49].
Different inorganic/organic composites for BTE have been studied; the most common fillers used are
bioceramics (hydroxyapatite, tricalcium phosphate), bioglass particles, and carbon nanotubes. The
reader is referred to the recent review by D’Este et al. for details of hydrogels specifically loaded with
calcium phosphate [50]. The mechanical properties of nanocomposites can be controlled either by
altering the properties of the matrix or of the nanofiller (i.e., concentration and size) and interfacial
bonding also has great importance as it may affect the effectiveness of load transfer.
3.1.1. Hydroxyapatite
Biomedical applications of nano-hydroxyapatite (nHap) bioceramics have gained increasing
interest due to their superior biological and biomechanical properties. Synthetic hydroxyapatite
exhibits a strong affinity to host hard tissues due to the chemical similarity with mineralised human
bone tissue [51]. Several studies have combined polymers and nHap to create composite hydrogels,
merging the desirable properties of the different organic and inorganic phases in order to achieve a
synergistic effect in the resultant composite properties including the enhancement of the mechanical
properties. Li et al. developed nHap/polyacrylamide composite hydrogels that presented higher
fracture tensile stress, higher extensibility, and higher compressive strength (35.8 MPa with 15% nHap
vs. 22 MPa for pure gel) in comparison to the parent hydrogels; furthermore, these composites
showed excellent shape recovery [52]. The authors justified the enhanced mechanical properties as
the result of the chelating effect and the hydrogen bonding between the polymer chains and nHap
particles. Natural polymers are also interesting biodegradable materials used in the formulation
of scaffolds for bone tissue engineering, mainly due to their similarities with extracellular matrix,
chemical versatility and overall good biological performance [53]. For example, silk fibroin displays
slow biodegradation, adjustable mechanical properties, high permeability to oxygen and water vapour,
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resistance to enzymatic degradation, favourable processability and biocompatibility, and, as such, has
attracted wide interest for a number of applications [54]. In addition, the mechanical integrity and low
inflammatory response of silk fibroin ensure its role as a promising material for osteogenic applications.
A nHap/silk fibroin composite hydrogel was developed by Ribeiro et al. [55]. In this composite, an
increase in nHap concentration corresponded to an increase in mechanical properties of the composite
with values of 90 and 100 kPa obtained for the compression modulus. Another natural polymer,
agarose, extracted from marine red algae, can form thermoreversible gels via physical crosslinking.
It is also a biocompatible and relatively bioinert material, which is promising for the formulation
of gel matrices for biomedical applications [56]. Hu et al. studied nHAp/agarose composites and
reported that with 70/30 organic/inorganic weight ratio the highest compressive strength value
(~400 MPa) was obtained, while a 65/35 weight ratio afforded the highest elastic modulus (~1100 MPa,
twofold that of pure agarose gel). This improvement in mechanical properties was justified by
the formation of intermolecular hydrogen bonds between the two components, with a role also
played by the average size (50 nm) of the well-dispersed spherical nHA particles [57]. Spherical
porous hydroxyapatite granules prepared by freeze drying of nHA/polyvinyl alcohol/gelatin slurry
droplets were encapsulated into oxidised alginate-gelatin-biphasic calcium phosphate hydrogel
networks by Sarker et al. Also in this case, an increase of granules amount led to an increase in
compressive strength due to mechanical interlocking of granules into the hydrogel matrix [58]. Chitin
is another biocompatible, biodegradable and bio-resorbable biopolymer with also antibacterial and
wound-healing abilities and low immunogenicity [59]. Chang et al. fabricated hybrid nHap/chitin
hydrogels that exhibited porous structure, high mechanical strength and excellent biocompatibility [60].
Addition of nHap increased 10 fold (274 kPa) the reported compressive strength of chitin only hydrogel.
The Young’s modulus of the hybrid hydrogel was ~320 kPa, compared to ~23 kPa of the chitin only
hydrogel. Also, combinations of natural and synthetic polymers are abundant in the literature.
For example, Arun Kumar et al. prepared a chitin/poly(caprolactone) hydrogel loaded with nHA.
The gel maintained good injectability after addition of nHA, and presented a significant increase in
elastic modulus [61].
3.1.2. Bioactive Glass
Bioactive glasses or bioglasses are inorganic amorphous materials that present variations of
composition based on the original bioglass (45S5): 45% silica (SiO2), 24.5% calcium oxide (CaO),
24.5% sodium oxide (Na2O), and 6% phosphorous pentoxide (P2O5) in weight percentage [62].
They display the ability to degrade at a controllable rate, releasing ions during this process and
develop a carbonated phosphate surface layer that allows them to chemically bond to the native
bone [63]. Bioactive glasses induce hydroxyapatite precipitation in the presence of a biological fluid,
resulting in enhanced mineralisation of the bone tissue [63,64]. They also possess the ability to
induce differentiation of mesenchymal cells into osteoblasts, to stimulate vascularisation and enhance
osteoblast proliferation [65,66]. These properties are primarily dependent on the glass composition
and microstructure [67]. Nevertheless, these materials are not suitable for load-bearing applications
because of their intrinsic brittleness. Alone, they exhibit poor flexibility and fatigue strength, so their
use in the formulation of composite hydrogels has been evaluated [68].
Gellan-gum represents a good candidate for the formulation of biocompatible scaffolds due
to its non-cytotoxicity, biodegradability and hydrophilic nature [69]. However, similarly to other
natural polymers, it presents relatively poor mechanical properties that narrow down its applications
in bone tissue engineering. Although a combination of physical (i.e., temperature) and chemical
crosslinking approaches (i.e., photocrosslinking) can produce gellan-gum hydrogels with tunable
physical and mechanical properties without affecting their biocompatibility, the mechanical properties
of the hydrogel alone are not suitable for bone tissue engineering [70]. Gantar et al. reinforced
gellan-gum hydrogels with a nanoparticulate glass to improve the microstructure and the mechanical
properties of the material [71]. The composite hydrogel scaffold containing 50% bioactive-glass
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exhibited a Young's modulus of ~1.2 MPa. Although this value is not sufficient to accommodate
biomechanical loading, when compared with the gellan-gum alone, the incorporation of the bioglass
significantly increased the Young's modulus from 0.4 to ~1.2 MPa and the failure stress increased from
0.02 to ~0.11 MPa. Photopolymerised poly(ethylene glycol) dimethacrylate hydrogels combined with
bioactive glass particles were synthetised and characterised by Killion et al. who demonstrated that
the incorporation of bioactive glass increases the mechanical strength of the composite material, with a
synergic action in which the bioactive glass absorbed the initial compressive load and the polymeric
matrix distributed the load between the reinforcement [72]. Lacroix et al. reported the synthesis
of a bioactive glass/gelatin composite scaffold with well-controlled porosity [73]. Compressive
loading was performed on pure bioactive glass and composite scaffolds: the glass foams presented a
step-by-step cracking characteristic of brittle materials, while the deformation of the gelatin-bioactive
glass composite remained in the linear elastic regime. Besides these improved mechanical properties
of the composite, its in vitro bioactivity was found to be as high as pure bioactive glasses.
3.1.3. Carbon Nanotubes (CNTs) and Other Carbon Materials
CNTs are allotropes of carbon composed of rolled up graphene sheets. According to the number
of sheets concentrically aligned to form one-dimensional nanostructures, single-wall nanotubes
(SWNTs) or multi-wall nanotubes (MWNTs) can be obtained [74]. CNTs present interesting and
unique properties such as extreme toughness, high electrical conductivity and high surface area [75];
and are of interest in tissue engineering as they can support the building of flexible and porous
structures similar to the extracellular matrix (ECM), an environment in which cells physiologically
migrate and proliferate to form tissues and organs [76]. Seo et al. developed a degradable membrane
composed by chitosan/silica incorporating functionalised-carbon nanotubes (f-CNT) for guided
bone regeneration [77]. In their study, the incorporation of 2% f-CNT substantially enhanced the
mechanical properties (tensile strength and elastic modulus) of CNT/chitosan/silica membranes
in comparison with chitosan/silica or bare chitosan membranes, while it did not have an effect on
elongation rates. In our lab, thermosensitive chitosan gels were reinforced with chitosan grafted
CNTs. It was found that CNTs not only increased the resistance of the gels to compression but,
due to their thermal properties, they also had a major role in determining the time of gelation
of the composite gels reducing it from around 1 h for chitosan only gels to about 7–8 min [78].
Nanocomposites of the biodegradable and biocompatible polymer poly(propylene fumarate) (PPF)
reinforced with three carbon nanostructures (SWNTs, ultra-short SWNTs (US-tubes) and fullerenes
(C60)) were fabricated by Sitharaman et al. The nanostructure size and surface area effects on the
rheological properties of un-cross-linked PPF dispersions, as well as the mechanical properties of
cross-linked nanocomposites were investigated as a function of the nanostructure concentration [79].
The US-tube nanocomposites showed the best mechanical enhancement effects. The mechanical
properties for US-tube nanocomposites peaked at concentrations of 0.5% and significantly enhanced
flexural and compressive mechanical properties (up to 200%), when compared to the pure PPF. The
study concluded that US-tubes and SWNTs contributed to better mechanical reinforcement than C60,
due to the higher aspect ratios and larger surface areas suggesting that the surface area of carbon
nanostructures may be more important than size for the mechanical reinforcement. Furthermore,
it was suggested that the fibril-like morphology of the SWNTs and US-tubes might also contribute to
the improved mechanical properties of the nanocomposites.
Other carbon structures have also been evaluated; Lalwani et al. compared the efficacy of two
dimensional (2D) carbon and inorganic nanostructures as reinforcing agents of crosslinked PPF
composites: single-walled graphene oxide nanoribbons, multi-walled graphene oxide nanoribbons,
graphene oxide nanoplatelets, and molybdenum di-sulfite nanoplatelets (MSNPs) [80]. The mechanical
properties (compressive modulus, compressive yield stress, flexural modulus and flexural yield stress)
of all the 2D nanostructure-reinforced nanocomposites as a function of 2D nanostructure concentration
(between 0.01% and 0.2%) were significantly higher in comparison to PPF. It was found that the
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mechanical reinforcement is closely dependent on the nanostructure morphology and follows the
order nanoplatelets > nanoribbons > nanotubes. The inorganic 2D nanostructure MSNPs showed
better mechanical reinforcement than 1D or other 2D carbon nanostructures. The 2D nanostructures
increased the crosslinking density of PPF nanocomposites compared to 1D nanostructures. Accordingly,
the authors suggested that harnessing the reinforcing potential of 2D nanostructures could lead to an
entire new class of ultra-strong, lightweight biomaterials for tissue engineering applications [80].
The inorganic components considered above enhance the mechanical properties leading to
reinforcement of the scaffold structure. Although the composite strategy is very promising, so far the
scaffolds obtained present mechanical properties far from resembling human bone. Limited literature
links properties such as fracture toughness or energy to failure of the composites. There are studies
that provide some mechanical analysis of the composites produced; however, few provide all the
characteristics that aid interpretation and comparison of the data. Data for bending/tension and
for measures of fracture toughness are not common, consequently creating several difficulties in
producing comparisons across studies as shown in Table 1 [81]. It is necessary to develop standard
procedures regarding the mechanical analysis of these materials, in order to facilitate comparison
between different studies and obtain a complete characterisation of the materials. One of the biggest
remaining challenges for composites it is to define and achieve appropriate mechanical requirements
of scaffolds for load-bearing defects.
Table 1. Mechanical properties of composite hydrogels containing inorganic components.
Scaffold Composite
Components
Organic Inorganic
Ratio
Compressive
Strength
(MPa)
Compression
Modulus
(KPa)
Elastic
Modulus
(MPa)
Reference
Poly(acrylamide) nHA 85:15 35.8 - - [52]
Silk fibroin nHA 85:15 - 109.8 - [55]
Agarose nHA 65:35 390 - 1104.4 [57]
Oxidized
alginate-gelatin-BCP Spherical HA 65:35 -
2.45 dry
0.05 wet - [58]
Chitin nHA 75:25 0.3 - 0.3 [60]
Gellam gum Bioglass 50:50 - - 1.2 [71]
PEG Bioglass 80:20 2.5 - 8 [72]
Chitosan/silica f-CNTs 98:2 - - 552 [77]
PPF Nano Carbon 0.2 - 2061 - [80]
Cortical bone - 130–180 - 12,000–18,000 [82]Trabecular bone - 4–12 - 100–500
3.2. Osteoinductive Composite Hydrogels: Controlled Delivery of Drugs and Growth Factors
While a well-designed scaffold can favour new bone formation in healthy patients by simply
providing a support for the growth of new tissue, the compromised bone homeostasis in osteoporosis
and other bone conditions hinders the healing process and requires the use of drugs and growth
factors to stimulate bone regeneration activity. In many cases, controlled and sustained release of these
pharmaceutical entities is required and hydrogels present an ideal platform for their release. Several
classes of drugs and different growth factors have been evaluated; these are discussed in detail below.
3.2.1. Bisphosphonates
Bisphosphonates (BPs) are one of the most important drug classes for treating bone tissue diseases
such as metastatic bone disease and osteoporosis [83]. They are carbon-substituted pyrophosphate
analogues [84] and they can reduce bone resorption, causing loss of osteoclastic activity and
accelerating osteoclast apoptosis by inhibiting farnesyl pyrophosphate synthase (an enzyme in the
3-hydroxy-2-methylglutaryl-coenzyme A (HMG-CoA) reductase pathway) [85]. The bisphosphonates
currently used in clinical practice are all biologically stable due to presence of a carbon atom
connecting the two phosphates (P-C-P) [86]: alendronate, clodronate, ibandronate, risedronate and
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zoledronate [87,88]. Each bisphosphonate presents a certain bone binding affinity: the higher the
affinity, the stronger the binding and slower the release and vice versa [85]. These molecules exhibit high
affinity for the mineralised bone matrix where they can be retained for several years, leading to potent
pharmacological effects on the bone [89]. The order of efficacy in inhibiting farnesyl pyrophosphate
synthase is zoledronate > risedronate > ibandronate > alendronate. The order in the kinetic binding
affinity to hydroxyapatite (Hap) is clodronate < etidronate < risedronate < ibandronate < alendronate
< pamidronate < zoledronate [90]. Controlled trials have highlighted that BPs reduce the incidence of
vertebral fractures by 40%–50% and non-vertebral fractures by 20%–40% [91]. Unfortunately, these
drugs present some drawbacks when orally administered, in particular low adsorption (0.6%–1.5%)
and high toxicity (esophageal disease, atrial arrhythmias, osteonecrosis of the jaw and atypical femur
fractures) [92].
Hydrogel systems have therefore been developed to allow controlled local delivery with minimal
invasiveness and time-persistence at the targeted area of the affected tissue. Despite the promising
effects of these drugs, BPs’ local release is still poorly explored. A common strategy investigated for
BPs controlled local delivery is to combine the controlled release from a biodegradable particulate
system with the diffusion barrier provided by a hydrogel scaffold. For example, Posadowska et al.
encapsulated alendronate in PLGA (poly(lactide-co-glycolide)) nanoparticles by a solid/oil/water
emulsification method (final drug loading 5%) [93]. The obtained nanoparticles (average diameter
230 nm) were then suspended in a gellan-gum (GG) hydrogel and the hydrogel matrix was cross-linked
with calcium ions to improve stiffness. PLGA was chosen because it is characterised by a tunable
degradation rate and FDA-approved, while GG is a low cost anionic natural polysaccharide widely
used for pharmaceutical purposes. This formulation allowed obtaining a release of 17% of the drug
after one day, while the entire encapsulated drug was released within 25 days. Moreover, in vitro
studies confirmed cytocompatibility of the formulation withMG-63 osteoblast-like cells and its capacity
to inhibit osteoclastic differentiation.
Furthermore, the high affinity of BPs for HAp can be exploited to facilitate controlled release
of these drugs from hydrogel scaffolds. Verron et al. [89] formulated a suspension of zoledronate
(Zol) granules loaded into calcium deficient apatite (CDA-Zol) in a cellulosic-derived hydrogel. CDA
was chosen to reinforce the osteoporotic site, while Zol to inhibit osteoclast resorption activity. The
implantation of CDA-Zol in distal femurs of osteoporotic female rats showed a significant increase
in bone volume fraction (BT/TV) and improved trabecular architecture compared to apatite alone.
Further histological examination did not show the presence of abnormal tissue (i.e., fibrosis, necrosis,
and granuloma) in the newly-mineralised area.
3.2.2. Statins
Statins are competitive inhibitors of HMG-CoA reductase. They are generally used for lowering
serum cholesterol [94], blocking the conversion of HMG-CoA to mevalonate. Hence, they are
commonly used for treating diseases such as hyperlipidemia and arteriosclerosis. More recently,
some studies have highlighted statins ability to increase new bone formation in cell cultures and in
animal models [95–97]. This anabolic effect has been firstly elucidated by an increased mineral density
in bones of type 2 diabetes patients when treated with statins [98]. Bradley et al. demonstrated that
these effects are associated with an increased expression of bone morphogenetic protein-2 (BMP-2)
and nitric oxide synthase [99]. However, clinical use of statins is limited by the really low systemic
availability (~2%) and serious side effects such as liver toxicity, acute hepatic failure and episodes
of myalgia [100–103]. Hence, local delivery (bypassing hepatic metabolism) could lead to higher
concentrations at the bone and a reduction of the side effects [101]. In this context, the formulation of
an appropriate scaffold is really important to achieve appropriate release kinetics and a local action.
Simvastatin (SIM) is recognised as the most potent statin in stimulating bone growth, with a biological
half-life of 1–3 h and susceptibility to cytochrome P450 metabolic activity [101]. This fungal metabolite
induces osteoblastic differentiation by increasing the expression levels of osteogenic markers such
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as alkaline phosphatase, osteocalcin and osteopontin [104]. Many studies have been carried out for
testing different materials and developing a suitable hydrogel scaffold [105].
Tanigo et al. successfully obtained a controlled release of SIM from gelatin/micelles composite
hydrogels [106]. In particular, SIM was firstly water-solubilised into lactic acid oligomer grafted gelatin
micelles. These micelles were then loaded into gelatin hydrogels, with tunable degradation rate based
on degree of crosslinking. The system allowed controlled release of SIM over 20 days and enhanced
the effect of the drug on bone regeneration in a rabbit tooth defect model. Sukul et al. prepared
a three components hydrogel scaffold for the controlled release of SIM composed of:   tricalcium
phosphate ( -TCP), an osteoconductive material; nanofibrillar cellulose, a slow degrading polymer
that can improve control over the release rate of the gel; and crosslinked gelatin as the main hydrogel
matrix [107]. The presence of nanofibers and  -TCP produced a scaffold with osteoconductive
properties and able to better control the drug release over a period of time exceeding 30 days.
Furthermore, a concentration of 0.5 µM SIM was identified as the most effective, both in vitro (highest
proliferation and differentiation of rat MSCs) and in vivo, in a 8-mm rat calvarial defect with a 33%
new bone formation after 8 weeks treatment (compared to 25% and 17% obtained with lower and
higher concentrations, respectively). Another well studied statin for bone regeneration applications
is fluvastatin. Benoit et al. explored the covalent binding of this drug to the gel forming polymer,
as a strategy for controlled release [100]. They used a biodegradable poly(lactic acid) spacer to load
fluvastatin to a poly(ethylene glycol) dimethacrylate hydrogel. The release rate of the drug was
controlled by the length of the spacer; the longer the spacer, the quicker the release due to the presence
of a higher number of hydrolysable bonds and an increased probability of release. This system showed
potential for controlled release over 40 days, in vitro the drug was able to induce hMSCs differentiation,
increase BMP-2 production and facilitate calcium deposition.
3.2.3. Growth Factors
Growth factors such as Bone Morphogenic Protein (BMP) are clinically relevant therapeutics
for tissue regeneration in musculoskeletal conditions. However, their current use has shown very
limited success because, even though collagen scaffolds have been developed for the controlled release
of BMP, the protein short half-life and diffusion to other tissues requires the use of very high doses
(10 µg) rendering the treatment costly and unsafe. Complications such as ectopic bone formation,
compromised airways function, swelling at the surgery site and neurological side effects have all
been reported in spinal fusion application of BMP [108,109]. Thus, developing new strategies for the
formulation and delivery of these growth factors could address the unmet clinical need for safe use of
bone inducing biomaterials. Furthermore, research has demonstrated that physiological bone healing
involves several different factors released at different times (Figure 1), indicating that release of a single
growth factor would be an oversimplification in an attempt to mimic the physiological response [36].
As seen in the case of controlled release of smaller drugs, also for the delivery of growth
factors, composite gels are used. The strategies for sustained release are very similar; in general,
a biodegradable or bioerodible multiparticulate system is introduced in the gel to further delay the
release of the entrapped macromolecule. Strategies such as core-shell and layer-by-layer deposition
are commonly used for the encapsulation of one or more growth factors [36].
The limitations of the current clinically available BMP-2 formulations have induced a lot of
research into improving the mechanism of controlled release of this protein, to provide better release
and address its short half-life and rapid local clearance. A commonly used strategy is that of exploiting
the known affinity of BMP-2 for heparin, therefore, including heparin into hydrogels. A study
conducted by Bhakta et al. demonstrated that both the initial burst, from the plain hyaluronic acid gel,
and the prolonged sustained release of BMP-2, obtained with the addition of heparin to hyaluronic
acid gels, were essential for efficient bone formation, and suggested that a compromise between
diffusion and affinity release must be found for best performance of the gel [110]. Chung et al.
exploited the same strategy in their fibrin gel loaded with heparin-functionalised nanoparticles in
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which the presence of heparin was instrumental in reducing the rate of release of BMP-2 and enhance
quantity and mineralisation of the newly formed bone in vivo [111]. Recent advances have looked at
introducing multiple control systems. This is, for example, the case of dual interaction nanoparticles
developed by Seo et al. [112]. They proposed a hydrogel that forms in situ after injection of polymeric
nanoparticles that bind to BMP-2 by both ionic and hydrophobic interactions; and demonstrated that
dual interactions were essential in generating a more effective formulation in vivo.
As recently reviewed by Bayer et al., growth factor delivery is moving towards the sequential
release of two factors from individual scaffolds with the release of a factor involved in angiogenesis
in the first release phase, followed by a growth factors such as BMP-2 in a second release phase [36].
Table 2 summarises the growth factors involved in bone healing that have been most commonly
studied for bone tissue engineering applications.
Table 2. Growth factors employed in bone tissue engineering applications [36].
Growth Factor Mechanism of Action Limitations
BMP-2 (Bone
morphogenic protein)
Induces osteoblasts proliferation and
mesenchymal cells (MSCs) differentiation
Induces VEGF-A secretion therefore has a role in
angiogenesis 1
Needs to be delivered in a
controlled manner
Variable outcomes have been seen
in humans
Limited capacity to initiate
vascular proliferation
VEGF (Vascular
endothelial growth factor)
Induces endothelial cells mitogenesis
Attracts MSCs and induces their differentiation
Delivered alone they lead to the
inability to produce organized
bone regeneration
PDGF (Platelet derived
growth factor)
Attracts cells that stabilise growing vasculature
Recruits MSCs
Upregulates VEGF production
FGF (Fibrobast
growth factor) Involved in the formation of new capillaries
IGF (insulin like
growth factor) Involved in adult neo angiogenesis
1 pro- or anti- osteogenic effect can be observed depending on the type of BMP used and the type of cells targeted.
Dyondi et al. carried out a study to investigate the effect of dual growth factor release [113]. They
developed a gellan-xanthan gum gel loaded with chitosan nanoparticles. BMP-2 was adsorbed on the
surface of the nanoparticles while FGF was loaded in the gel. A comparison between single and dual
growth factor release was carried out in vivo and showed that the combined release of the two growth
factors resulted in a higher ability to promote osteoblast proliferation and differentiation. Interestingly,
the gels also presented antimicrobial properties.
Doubtlessly, as demonstrated by the examples reported above, due to their physical and chemical
flexibility, hydrogel formulations, and, even more so, hydrogel composite formulations, represent an
essential tool in the development of controlled release systems for the local delivery of therapeutic
molecules to the bone.
3.3. Osteogenic Composite Hydrogels
Osteogenesis is characterised by a high number of cells compared to the mature bone tissue. These
are osteoprogenitor cells that produce the extracellular matrix, which will support bone formation and
will be later resorbed [114]. A good strategy to be employed in bone regeneration is that of recreating the
environment in which osteogenesis takes place; this can be mimicked with a 3D hydrogel network that
allows osteoprogenitor cells to proliferate and differentiate into osteoblasts. In fact, hydrogels are able
to create a complex and dynamic network that replicates the characteristics of the extracellular matrix
providing physical structure, mechanical integrity and biocompatibility with the host tissue [115,116].
Studies have investigated the use of different cell types that will be considered in detail below [12].
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3.3.1. Mesenchymal Stem Cells
Stem cells are undifferentiated cells capable of self-renewal and differentiation into specialised
cells [102]. Mesenchymal stem cells (MSCs), otherwise known as bone marrow stromal cells, are
multipotent adult stem cells which can be found in the bone marrow, among other sites [41,98]. MSCs
can proliferate in vitro and differentiate into diverse mesenchymal lineages (adipocytes, chondrocytes,
myocytes, osteoblasts and tenocytes) in response to appropriate signaling by chemicals, growth factors
and hormones [98,117]. Interestingly, MSCs possess trophic factors that suppress the local immune
system, decreasing the risk of autoimmune rejection and promoting local vascularisation [12,118,119].
Moreover, they are easy to isolate from bone marrow and to manipulate. In fact, they can be enriched
to obtain a relatively pure population of cells and differentiate into osteoblasts that are capable of
secreting extracellular matrix [102]. Many researches are focusing on the identification of a suitable
three-dimensional scaffold for cell transplantation to promote the localised healing of the desired
tissue. The aim is to develop a scaffold that is both biodegradable and injectable, in order to allow
the growth of the new tissue as degradation of the polymer scaffold occurs, and to perform a single
minimally invasive procedure [120]. However, the shortcomings of current methods underline the
need for combining our understanding of what cell types can form bone and what scaffold best
facilitates the differentiation of these cells [121]. Several hydrogels including alginate, collagen, fibrin
glue, hyaluronic acid, oligo[poly(ethylene glycol) fumarate], pluronic F127 and silk fibroin have been
studied to encapsulate MSCs and to promote their osteogenic differentiation [102,104,122].
Nuttleman et al. successfully proposed the encapsulation of hMSCs into a photocrosslinkable,
injectable scaffolding system based on a dimethacrylated PEG (MW 4.6 kDa) as the hydrogel
precursor [123]. These gels presented an excellent cytocompatibility (relative cell survival: 99%)
and osteogenic-specific differentiation was confirmed by the expression of osteonectin, osteopontin
and alkaline phosphatase genes. Finally, a staining procedure revealed extensive mineralisation of
the PEG hydrogels. Dimethacrylated PEG is also suitable to prepare scaffolds via the novel approach
of bioprinting. Gao et al. [124] loaded hMSCs on photocrosslinked PEG-hydrogel scaffolds enriched
with natural cell binding motifs (Arg-Gly-Asp or RGD peptide and matrix metalloproteinase-sensitive
peptide). The bioprinting process allowed them to condense multiple steps of scaffold fabrication
into one single step and to obtain a matrix that leads to a homogeneous development of bone and
cartilage. Moreover, the bioprinted PEG-peptide scaffold showed excellent mineral and cartilage matrix
deposition and the addition of the peptides showed a sustained effect over time on cell differentiation
compared to the polymer only gel.
Another extensively studied polymer for BTE is hyaluronic acid (HA), a naturally derived, linear,
high molecular weight polymer and one of the major components of ECM [125]. Many studies
have been carried out in order to modify its structure, allowing the attachment of therapeutic drugs,
functional groups, crosslinkers, and other bioactive moieties to HA [118,119]. Kim et al., following a
similar approach to the one by Nuttleman et al. described above, prepared an acrylated HA hydrogel
for loading BMP-2 and hMSCs [125]. The formulation had a gelation time of 10 min at physiological
conditions; however, mechanical testing (complex modulus 1.8 kPa, elastic modulus 1.8 kPa) revealed
that this hydrogel was not strong enough for load bearing applications. Even though the formulation
presented a relatively low in vitro cell viability (72% within two days, increased to 81% with the
addition of BMP-2), the in vivo results showed that it was able to induce angiogenesis and osteogenesis.
The HA hydrogel alone demonstrated good compatibility but no activity, while the addition of BMP-2
and hMSCs revealed a synergistic effect with formation of thicker and denser new bone, compared to
the hydrogels containing only one of the two components.
Collage type I matrices are currently used in clinical practice for example for the delivery of
BMP-2 (InductOs); collagen is one of the most abundant fibrous proteins in the human body, found in
tendons, ligaments, bone, teeth, skin, arteries and, in general, in extracellular matrix [126]. Collagen
is a common tissue culture matrix due to its ability to facilitate cell attachment and its cell-based
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degradation. The ability of collagen type I hydrogels to favour attachment, migration and proliferation
of rat bone marrow stromal cells was demonstrated by Hesse et al. [127].
Fibrin glue is another polymeric gel already exploited in the clinic, which has attracted interest in
bone regeneration applications for the implantation of stem cells [128]. Seebach et al. implanted
fibrin glue hydrogels loaded with rat derived MSCs into rat femoral bone defects to test host
cell-recruitment, immunomodulation and tissue regeneration [116]. Results highlighted fibrin-MSC
composite promoted host macrophage invasion, in comparison to cell-free fibrin hydrogels, due to the
MSCs’ expression of trophic factors (e.g., IL-6, VEGF and MIP-2). Then, MSCs seemed to stimulate
femoral bone healing, despite a light induction of a pro-inflammation process (TNF-↵ and IL-1 ).
MSCs’ harvesting from the bone marrow requires painful procedures of aspiration from the iliac
crest or from bone marrow biopsies that can anyway give low cells yields [121]. Hence, due to these
practical constraints, researches have focused on the use of multi-lineage mesenchymal progenitor
cells from other sources.
3.3.2. Adipose Derived Stem Cells
Human adipose-derived stem cells (ASCs) are a subset of MSCs that can be found in human
adipose tissue [129]. The adipose tissue is a highly complex tissue that consists of mature adipocytes
(90% of the total volume) and a stromal vascular part composed by pre-adipocytes, fibroblasts, vascular
smooth muscle cells, endothelial cells, resident monocytes/macrophages lymphocytes and ASCs [130].
ASCs are an interesting cell-lineage for regenerative medicine since they present morphological,
immunological and phenotypical properties similar to stem cells isolated from bone marrow and
umbilical cord blood, with some advantages [129,131,132]. In fact, ASCs have the potential to
differentiate into bone, cartilage, tendons, skeletal muscle and fat under specific conditions and
they are easy to access, abundant in the subcutaneous adipose tissue and isolated by an uncomplicated
enzyme-based procedure [132]. The combination of ASCs with biomaterial scaffolds is currently a very
promising strategy for restoring tissue functions, but further advances are needed.
Heo et al. [133] loaded ASCs on a photo-curable gelatin-gold nanoparticle (GNPs) hydrogel in
order to study the effects of GNPs on stem cells. According to recent studies, GNPs have been shown
to have a positive effect on osteogenesis of MSCs and MC3T3-E1 osteoblast-like cells, other than
presenting low costs and non-toxicity [134,135]. In Heo’s study, the hybrid hydrogel was obtained by
irradiation of the mixture of the photo-initiator and methacrylated gelatin leading to successful loading
of the GNPs inside the hydrogel network. Assays showed an increase in viability and osteogenic
differentiation of ASCs in comparison with the hydrogel only and similar results in comparison with
BMP loaded hydrogel, both in vivo and in vitro. Moreover, all the studied hydrogels had a positive
effect on bone healing in the defect sites and were biologically degradable by collagenase.
Graphene, a two dimensional carbon structure that presents unique physical properties such as
high surface area, high mechanical strength, high electrical conductivity and ease of functionalization,
has been recently reported to be able to form hydrogels and to promote in vitro osteogenic
differentiation and proliferation of stem cells [136–138]. Lyu et al. examined the osteoinductivity
of hASCs loaded self-supporting graphene hydrogels (SGH) obtained by electrostatic stabilisation of
graphene and its gelation by filtration [139]. They found that in comparison to conventional graphene
and carbon fibre films, SGH films had higher mechanical strength, flexibility, cell viability (after one
day culture, 95.43% ˘ 0.96%), mineralisation and osteoinductivity. This finding opens new avenues in
the development of hydrogels for bone regeneration applications.
3.3.3. Stem Cells from Human Exfoliated Deciduous Teeth
Stem cells from human exfoliated deciduous teeth (SHEDs) have been recently identified as an
alternative source of multipotent adult stem cells because of their capacity to differentiate into various
cell lineages: neural cells, odontogenic cells, osteogenic cells and adipocytes [140,141]. Moreover, they
were reported to have a higher proliferation rate compared to MSCs and dental pulp stem cells and to
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be easier and more convenient to isolate [140–142]. Unfortunately, few studies about the loading of
SHEDs into hydrogels have been published until now, underling the importance of further research in
this field.
Su et al. [140] investigated the effects of chitosan/gelatin/ -glycerophosphate thermosensitive
hydrogels containing strontium phosphate or tricalcium phosphate (TCP) on the osteogenic
differentiation of SHEDs in vitro. Strontium has been added to the scaffold since it has been shown
to positively influence bone formation and inhibiting bone resorption [143,144]. Scanning electron
microscopy analysis of the surface revealed that all the studied hydrogels presented homogenous
porous structures (100–300 µm) with high interconnected channels that had high cytocompatibility.
Nevertheless, the presence of bioceramic supplements, allowed continuous proliferation of cells for
longer cultivation times (14 days). Strontium hydrogels also significantly increased calcification and
expression of osteogenic genes compared to tricalcium phosphate.
3.3.4. Embryonic Stem Cells
Embryonic stem cells (ESC) are pluripotent stem cells derived from the inner cell mass of
blastocysts and they can differentiate to form cell populations derived from ectoderm, mesoderm
and endoderm, hence, any cell type [145]. They possess a nearly unlimited self-renewal capacity
and their growth is not restricted by contact inhibition and proliferative senescence. As reported by
Li et al., ESCs are a promising cell source for regenerative medicine, even though some challenges
need to be overcome, such as achieving large-scale expansion culture systems, mainly due to the
involvement of animal components [146,147]. Although the propagation of embryonic stem cells has
usually been carried out in two-dimensional (2D) systems, 3D scaffolds would facilitate convenience in
transplantation and consistency in cell performance and scalability in number [148]. Hence, the use of
natural and synthetic hydrogels for hESC propagation in 3D has been proposed [148–152]. However,
the study of ESCs properties and propagations on hydrogels for bone tissue engineering needs to be
further explored.
Zur Nieden et al. studied the chemical modification of gelatin hydrogels through glyceraldehyde
cross-linking to provide a suitable scaffold for ESC osteogenesis [115]. On one hand, gelatin was used
as the main component of the matrix for its desirable properties: low toxicity, easy sterilisation and
limited higher ordered protein structure. On the other hand, glyceraldehyde is an ideal cross-linker
since it is non-toxic and makes gelatin stable at 37 ˝C. The obtained gel was able to provide an initial
soft non-adhesive surface for promoting the formation of embryoid bodies and to provide a harder
surface that gradually disappeared as osteoblasts differentiated.
4. Concluding Considerations
The wealth of research into hydrogels formulations for bone regeneration applications
demonstrates the great potential of these systems. Hydrogels fulfill many of the requirements of
ideal scaffold such as injectability, biocompatibility and biodegradation. Furthermore, they can easily
be chemically modified or co-formulated with other components that bestow further properties such
as osteoconduction, osteoinduction and oesteogenicity. Hydrogels can be composed of a great variety
of synthetic and natural polymers and their capacity to function as a diffusion barrier for both small
and large molecular weight drugs has been widely exploited for controlled drug delivery applications.
All proposed systems seem to provide incremental improvements to the performance of hydrogels,
but, perhaps, the development of fundamentally innovative ideas is the key to moving to clinically
applicable formulations. Approaches such as bioprinting or the development of fundamentally new
hydrogels such as those formed by graphene oxide could open up novel and more promising avenues
towards the successful clinical use of composite hydrogels for bone regeneration.
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Abbreviations
The following abbreviations are used in this manuscript:
ASCs adipose-derived stem cells
BFGF basic fibroblast growth factor
BMP bone morphogenic protein
BPs bisphosphonates
BTE bone tissue engineering
C60 fullerenes
CaP calcium phosphate
CDA calcium deficient apatite
CNTs carbon nanotubes
Cs chitosan
ECM extracellular matrix
ESC embryonic stem cells
f-CNT functionalized-carbon nanotubes
FGF fibroblast growth factors
GG gellan gum
GNPs gold nanoparticle
HA hyaluronic acid
Hap hydroxyapatite
HMG-CoA 3-hydroxy-2-methylglutaryl-CoA
hMSCs human mesenchymal stem cells
HSC hematopoietic stem cells
IGF insulin like growth factor
MSC mesenchymal stem cells
MSNPs molybdenum di-sulfite nanoplatelets
MWNTs multi-wall nanotubes
nHap nanohydroxyapatite
PDGF platelet-derived growth factors
PEG polyethylene glycol
PLGA poly(lactide-co-glycolide)
PPF poly(propylene fumarate)
PTH parathyroid hormone
SGH self-supporting graphene hydrogels
SHEDs stem cells from human exfoliated deciduous teeth
SIM simvastatin
SWNTs single-wall nanotubes
TCP tricalcium phosphate
TE tissue engineering
TGF-  transforming growth factor
TNF-↵ tumour necrosis factor-↵
US-tubes ultra-short single-wall nanotubes
VEGF vascular endothelial growth factor
Zol zoledronate
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